Jan 07, 2025 9:12am EST MAIA Biotechnology Announces Clinical Supply Agreement with BeiGene for Upcoming Phase 2 Trials in Three Cancer Indications
Dec 19, 2024 8:47am EST MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings
Dec 16, 2024 8:37am EST MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas
Dec 03, 2024 8:17am EST MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer
Nov 07, 2024 8:47am EST MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement
Nov 05, 2024 9:45am EST MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Oct 15, 2024 8:15am EDT MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics
